Gene therapy-based replacement of defective enzymes in target tissues, which is a current effort in the treatment of metabolic diseases (51), may be an ultimate goal help to improve the therapeutic opportunities of FH-deficient RCC. Here, FH is linked to renal cell carcinoma.